DoseWatch Corporation offers solutions to patients’ medication non-compliance through its revolutionary smart blister packaging technology, a $150 billion health care cost to the U.S. health care system.

Columbus, Ohio, 12/13/2005 — 125,000 people die every year from medication non-compliance representing twice the number of those killed in automobile accident, and a cost of $1,000 per non compliant patient versus $250 for a compliant one. A solution to this national health care crisis looms on the horizon, thanks to DoseWatch Corporation’s patented technology. Nadir Benouali, the founder and CEO of DoseWatch Corporation has devoted more than ten years of his life, traveled to 4 different continents to just develop an understanding to medication distribution, administration and control. He did not only taught seminars on health care management across the world, but also holds a patent that can revolutionize patient medication compliance.

Monitoring and reporting patient non-compliance during a treatment or a clinical trial can be daunting. Many academic institutions as well as private companies tried to address the issue of patients’ non-adherence to medication regimens, however, to date, not a single technology resolved the problem of patients’ prescription non-compliance. On the clinical trials front, pharmaceutical companies rely on the enrolled patients’ own reporting as well as the clinicians.

The research and development during the last decade focused on the design of child proof and senior friendly pharmaceutical packaging models as well as pill counter, and clinical trials enrolled patients’ calendars etc. Nevertheless, the solution addressing accurately, efficiently and economically patients’ non-compliance is still being sought by the pharmaceutical industry.

DoseWatch Corporation answers all the above problems while keeping in mind a user friendly technology that can not only tell whether a patient has consumed appropriately his/her medication and followed his/her physician’s prescribed regimen, but also reminds patients automatically to take their medications. Furthermore, this new technology can detect erroneous compliance. For example, if a patient lies to his physician whether he or she was compliant with the treatment, through DoseWatch’s technology, a physician or a pharmacist can check whether the patient has indeed complied.

According to Nadir Benouali, “the questions we get most is how can you tell whether a patient took his medication?’ My answer is always yes we can because of a sophisticated proprietary technology that we use alongside our smart blister packaging. However, our first aim is to aid patients comply with prescription drugs, and to do this, we also take care of everything else for the patient like we can remind the patient on time and every time automatically to take his medication while we can watch for adverse effects and warn the patient ahead of time. Our technology will also take care of all refills automatically while physicians and pharmacists can rely on us to offer them relevant data on their patients’ behavior with prescription medications.”

To pursue its challenging development program, DoseWatch Corporation is seeking financing to accelerate the development of its core and sub-core technology. The funds will support clinical programs as well as recruiting key personnel to the organization and to secure its leadership position through its partnering strategy regarding the use of DoseWatch smart blister packaging technology with potential contract research organizations (CROs), and other pharmaceutical companies.

The intellectual property portfolio for DoseWatch smart blister packaging is extensive, and it has recently been accepted by the U.S. Patent and Trademark Office (“USPTO”). “Our IP protects our core technology while other patents are pending. This will give us the opportunity to extend the protection of any smart blister/bottle packaging that would be developed and commercialized using DoseWatch Corporation’s technology,” said Nadir Benouali, CEO of DoseWatch Corporation.

For additional information or a sample copy, Contact: info@dosewatch.com

Through DoseWatch patented technology, physicians, pharmacists, insurance companies and pharmaceutical corporations along with other state and federal government agencies will come to appreciate the user friendliness of this new technology, but above all its ability in bringing a solution to the patients’ non-adherence to their medication regimens.

As much as DoseWatch Corporation is a young start-up company, its ambition is to become a leader by which the industry will be measured by.

# # #